At a glance
ClinicalIndex Comparison RecordN/ACompleted· 57 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Open-label, Multicenter, National, Non-interventional Phase IV Trial of the Effectiveness, Safety and Tolerability of Tarceva as Second-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC), After Failure of First-line Treatment With a Pemetrexed-containing Chemotherapy Regimen
In Brief
An observational study evaluating Erlotinib for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 57 participants across 21 sites.
Detailed Summary
This prospective, multicenter observational study will evaluate the efficacy, safety, and tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after pemetrexed-containing first-line chemotherapy. Eligible patients will be followed until withdrawal of consent, lost-to-follow-up, or study termination, whichever occurs first.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedAug 2012
Primary CompletionAug 2013
TodayJul 2026
First PostedAug 14, 2012
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.9 years ago
Interventions
Erlotinibdrug
Erlotinib was supplied as tablets in the retail product Tarceva.